Cargando…
Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free (225)Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy
Actinium-225 ((225)Ac) is a promising radionuclide used in targeted alpha therapy (TAT). Although (225)Ac labeling of bifunctional chelating ligands is effective, previous in vivo studies reported that free (225)Ac can be released from the drugs and that such free (225)Ac is predominantly accumulate...
Autores principales: | Yoshimoto, Mitsuyoshi, Yoshii, Yukie, Matsumoto, Hiroki, Shinada, Mitsuhiro, Takahashi, Masashi, Igarashi, Chika, Hihara, Fukiko, Tachibana, Tomoko, Doi, Ayano, Higashi, Tatsuya, Fujii, Hirofumi, Washiyama, Kohshin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540721/ https://www.ncbi.nlm.nih.gov/pubmed/34683999 http://dx.doi.org/10.3390/pharmaceutics13101706 |
Ejemplares similares
-
Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64
por: Yoshii, Yukie, et al.
Publicado: (2023) -
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized (64)Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study
por: Hihara, Fukiko, et al.
Publicado: (2022) -
Tuning aminopolycarboxylate chelators for efficient complexation of trivalent actinides
por: Pilgrim, Corey D., et al.
Publicado: (2023) -
Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET
por: Matsumoto, Hiroki, et al.
Publicado: (2022) -
ET-7 EVALUATION OF HYPOXIA-TARGETING RADIOPHARMACEUTICAL(64)CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA MODEL
por: Yoshii, Yukie, et al.
Publicado: (2022)